Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | CPS1 | P31327 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23620982 | 0.89 | GPR119 (0.52) | CA2GPR119CA1CA9CA12 | |
| SCHEMBL23628462 | 0.82 | CA2 (0.58) | CA2CA1CA9CA12CA14 | |
| SCHEMBL18668643 | 0.81 | CA2 (0.65) | CA2GPR119CA1CA9CA12 | |
| SCHEMBL20397185 | 0.81 | CA2 (0.65) | CA2GPR119CA1CA9CA12 | |
| SCHEMBL18668645 | 0.81 | CA2 (0.65) | CA2GPR119CA1CA9CA12 | |
| SCHEMBL29571591 | 0.81 | CA2 (0.47) | CA2GPR119CA1CA12CA7 | |
| SCHEMBL18668480 | 0.81 | CA2 (0.47) | CA2GPR119CA1CA12CA7 | |
| SCHEMBL23628480 | 0.79 | CA2 (0.57) | CA2CA1CA9CA12CA14 | |
| SCHEMBL28723643 | 0.79 | CA2 (0.52) | CA2CA1CA9CA12CA14 | |
| Hydrochloric Acid SCHEMBL22205231 | 0.78 | CA2 (0.56) | CA2CA1CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353178-B1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-07-14 | — | — | EP | disclosed |
| US-20200223854-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-10647719-B2 | Bicyclic compounds as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180215765-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-08-02 | — | — | US | disclosed |
| EP-3353178-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017050791-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223854-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | ATXN2, ATXN2L, ATXN10 | CA2 238/4885GPR119 3243/4885CA1 1155/4885 |
| US-20180215765-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | ATXN2, ATXN2L, ATXN10 | CA2 473/4885GPR119 3213/4885CA1 1536/4885 |
| US-10647719-B2 | Bicyclic compounds as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | CA2 238/4885GPR119 3243/4885CA1 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.